We are live on
!
Find out more
ACM
Alethea Capital Management Portfolio holdings
AUM
$195M
1-Year Est. Return
51.17%
This Fund
S&P 500
This Quarter
Est. Return
+6.54%
1 Year Est. Return
+51.17%
3 Year Est. Return
+200.24%
5 Year Est. Return
+277.75%
10 Year Est. Return
+2,049.08%
AUM
$93.5M
AUM Growth
-$1.2M
(-1.3%)
Cap. Flow
-$5.31M
Cap. Flow
% of AUM
-5.68%
Top 10 Holdings %
Top 10 Hldgs %
81.33%
Holding
72
New
14
Increased
7
Reduced
14
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelon
EXC
|
+$620K |
| 2 |
American International
AIG
|
+$602K |
| 3 |
Ventas
VTR
|
+$591K |
| 4 |
Pfizer
PFE
|
+$578K |
| 5 |
Norfolk Southern
NSC
|
+$566K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$1.9M |
| 2 |
PepsiCo
PEP
|
+$740K |
| 3 |
Fastenal
FAST
|
+$735K |
| 4 |
Ford
F
|
+$699K |
| 5 |
Public Storage
PSA
|
+$695K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.01% |
| 2 | Financials | 3.85% |
| 3 | Consumer Staples | 3.05% |
| 4 | Industrials | 2.91% |
| 5 | Real Estate | 1.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$12.4B
| $54.6M | 58.4% |
759,944
-25,739
| -3% | -$1.9M |
|
|
RNAM
2
DELISTED
Avidity Biosciences
RNAM
| $9.42M | 10.08% |
849,651
| – | – |
|
3
Kura Oncology
KURA
$922M
| $3.53M | 3.77% |
333,445
-30,328
| -8% | -$359K |
|
4
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
| $2.4M | 2.56% |
23,278
-922
| -4% | -$95.6K |
|
|
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
| $1.84M | 1.97% |
81,384
-2,476
| -3% | -$58.2K |
|
6
Merck
MRK
$324B
| $959K | 1.03% |
8,312
+4,312
| +108% | +$490K |
|
7
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
| $918K | 0.98% |
10,000
-1,000
| -9% | -$91.6K |
|
8
Dow Inc
DOW
$21.6B
| $831K | 0.89% |
15,607
+10,307
| +194% | +$548K |
|
9
Duke Energy
DUK
$102B
| $795K | 0.85% |
8,856
+5,856
| +195% | +$553K |
|
10
CVS Health
CVS
$137B
| $754K | 0.81% |
10,904
+684
| +7% | +$48.7K |
|
|
11
Pfizer
PFE
$140B
| $746K | 0.8% |
20,349
+14,849
| +270% | +$578K |
|
|
SPPI
12
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $720K | 0.77% |
750,465
-37,508
| -5% | -$37.1K |
|
|
13
American International
AIG
$41.9B
| $646K | 0.69% |
+11,219
| New | +$602K |
|
|
14
Ventas
VTR
$48.9B
| $616K | 0.66% |
+13,035
| New | +$591K |
|
|
15
Exelon
EXC
$48.6B
| $611K | 0.65% |
+14,988
| New | +$620K |
|
|
16
Norfolk Southern
NSC
$78.8B
| $605K | 0.65% |
+2,666
| New | +$566K |
|
17
Best Buy
BBY
$18B
| $592K | 0.63% |
+7,219
| New | +$539K |
|
18
Hormel Foods
HRL
$13.9B
| $570K | 0.61% |
14,170
+9
| +0.1% | +$361 |
|
19
Oneok
OKE
$58.7B
| $549K | 0.59% |
+8,893
| New | +$550K |
|
20
Kraft Heinz
KHC
$30.4B
| $519K | 0.55% |
+14,612
| New | +$562K |
|
21
Healthpeak Properties
DOC
$15.4B
| $517K | 0.55% |
+25,722
| New | +$534K |
|
22
Alexandria Real Estate Equities
ARE
$8.88B
| $511K | 0.55% |
+4,501
| New | +$536K |
|
23
Zions Bancorporation
ZION
$10.1B
| $507K | 0.54% |
+18,880
| New | +$524K |
|
24
Citizens Financial Group
CFG
$30.4B
| $485K | 0.52% |
+18,606
| New | +$513K |
|
25
Apple
AAPL
$4.89T
| $456K | 0.49% |
2,351
| – | – |
|
Similar funds
WM
LWA
CPI
WAL
NLWP
ICMARC
RAM
MHFA
Alethea Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Alethea Capital Management held 72 positions worth $93.5M, down 1.3% from $94.7M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Alethea Capital Management withdrew a net $5.31M in Q2 2023, closing 21 positions and reducing 14 holdings. Its most notable exit was Fastenal, an estimated $735K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Consumer Staples.
Against the trend, Alethea Capital Management opened a new position in Exelon worth $611K.
- Alethea Capital Management's largest Q2 2023 buy was Exelon: 14,988 shares worth $611K.
- Alethea Capital Management added most to Pfizer in Q2 2023, an estimated $578K increase.
- Alethea Capital Management's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $1.9M.
- Alethea Capital Management fully exited Fastenal in Q2 2023, selling an estimated $735K.
- Alethea Capital Management's ten largest holdings make up 81% of its $93.5M portfolio in Q2 2023.
- Alethea Capital Management opened 14 new positions and closed 21 in Q2 2023.
- Alethea Capital Management's portfolio value fell 1.3% quarter-over-quarter to $93.5M.
Based on Alethea Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.